Pfizer News and Research RSS Feed - Pfizer News and Research

Little-known supportive cells in brain may play major role in cognitive function

Little-known supportive cells in brain may play major role in cognitive function

When you're expecting something-like the meal you've ordered at a restaurant-or when something captures your interest, unique electrical rhythms sweep through your brain. [More]
TransCelerate selects Cognizant to develop first-of-its-kind, subscription-based platform

TransCelerate selects Cognizant to develop first-of-its-kind, subscription-based platform

Cognizant today announced that it has been selected by TransCelerate BioPharma Inc., a non-profit organization with membership representation from 19 major pharmaceutical companies, to develop a first-of-its-kind, subscription-based platform that will transform the way clinical sites collaborate with pharmaceutical companies on clinical trials. [More]
PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014" report

PharmaBoardroom's "Healthcare and Life Sciences Review Poland 2014", is now available for free download. The report explores one of Europe's largest pharma markets, and looks at the delicate balance between a strong and growing economy, and healthcare legislation that many complain is negatively affecting the pharmaceutical market. [More]
Study: Fish oil supplements reduce cognitive decline, brain atrophy in older adults

Study: Fish oil supplements reduce cognitive decline, brain atrophy in older adults

Rhode Island Hospital researchers have completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older adults. [More]
Pfizer to in-license Absorption Systems' BCRP-MDCK cells

Pfizer to in-license Absorption Systems' BCRP-MDCK cells

Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein). [More]

Dyadic International announces details regarding new Bakenzyme project

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project. [More]
Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases. [More]
Combination of cognitive behavioral therapy and medication reduces relapse in depressed youths

Combination of cognitive behavioral therapy and medication reduces relapse in depressed youths

Cognitive behavioral therapy in addition to medication improves the long-term success of treatment for children and adolescents suffering from depression, a new UT Southwestern Medical Center study indicates. [More]
Testosterone therapy does not increase men's risk for heart attack, shows UTMB study

Testosterone therapy does not increase men's risk for heart attack, shows UTMB study

Testosterone prescriptions for older men in the United States have increased more than three-fold over the past decade. Recent studies linking testosterone use with increased risk of heart attack and stroke have caused widespread concern among patients and their families. [More]
Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. [More]
Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer Inc. and Cellectis today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. [More]

Medtronic to buy Covidien

Combining the two huge medical device companies will have global implications. Medtronic agreed on Sunday to buy Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping it reduce its corporate taxes. [More]
‘Surprising’ effect of growth hormone on BMI in normal-weight children

‘Surprising’ effect of growth hormone on BMI in normal-weight children

Researchers have found that the body mass index standard deviation score increases in normal-weight children receiving growth hormone treatment. [More]
Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology. [More]
Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19. [More]
NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

The National Comprehensive Cancer Network Oncology Research Program, in collaboration with Pfizer Independent Grants for Learning & Change, recently awarded six independent grants to health care institutions following a joint Request for Proposals (RFP) focused on the development and adoption of evidence-based initiatives to improve patient care and outcomes in renal cell carcinoma and hematologic malignancies. [More]
KineMed renews non-exclusive research collaboration with Pfizer

KineMed renews non-exclusive research collaboration with Pfizer

KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. [More]
Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. [More]